Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 178


Marked differences in prediabetes- and diabetes-associated comorbidities between men and women-Epidemiological results from a general population-based cohort aged 6-80 years-The LEAD (Lung, hEart, sociAl, boDy) study.

Breyer MK, Ofenheimer A, Altziebler J, Hartl S, Burghuber OC, Studnicka M, Purin D, Heinzle C, Drexel H, Franssen FME, Wouters EFM, Harreiter J, Kautzky-Willer A, Breyer-Kohansal R.

Eur J Clin Invest. 2020 Jan 29:e13207. doi: 10.1111/eci.13207. [Epub ahead of print]


ESC Guidelines revisited.

Drexel H, Milbradt S.

Eur Heart J Cardiovasc Pharmacother. 2020 Jan 13. pii: pvz083. doi: 10.1093/ehjcvp/pvz083. [Epub ahead of print] No abstract available.


Data on the power of high betatrophin to predict cardiovascular deaths in coronary patients.

Leiherer A, Ebner J, Muendlein A, Brandtner EM, Zach C, Geiger K, Fraunberger P, Drexel H.

Data Brief. 2019 Dec 12;28:104989. doi: 10.1016/j.dib.2019.104989. eCollection 2020 Feb.


Adherence to statin therapy favours survival of patients with symptomatic peripheral artery disease.

Dopheide JF, Veit J, Ramadani H, Adam L, Papac L, Vonbank A, Kaspar M, Rastan A, Baumgartner I, Drexel H.

Eur Heart J Cardiovasc Pharmacother. 2019 Dec 10. pii: pvz081. doi: 10.1093/ehjcvp/pvz081. [Epub ahead of print]


ESC Position Paper on statins adherence and implementation of new lipid-lowering medications: barriers to be overcome.

Drexel H, Coats AJS, Spoletini I, Bilato C, Mollace V, Filardi PP, Rosano GMC.

Eur Heart J Cardiovasc Pharmacother. 2019 Dec 24. pii: pvz079. doi: 10.1093/ehjcvp/pvz079. [Epub ahead of print]


High betatrophin in coronary patients protects from cardiovascular events.

Leiherer A, Ebner J, Muendlein A, Brandtner EM, Zach C, Geiger K, Fraunberger P, Drexel H.

Atherosclerosis. 2020 Jan;293:62-68. doi: 10.1016/j.atherosclerosis.2019.11.011. Epub 2019 Nov 15.


Evaluation of the associations between circulating microRNAs and kidney function in coronary angiography patients.

Muendlein A, Geiger K, Leiherer A, Saely CH, Fraunberger P, Drexel H.

Am J Physiol Renal Physiol. 2020 Feb 1;318(2):F315-F321. doi: 10.1152/ajprenal.00429.2019. Epub 2019 Dec 9.


Real-time PCR based HLA-B*27 screening directly in whole blood.

Geiger K, Zach C, Leiherer A, Fraunberger P, Drexel H, Muendlein A.

HLA. 2020 Mar;95(3):189-195. doi: 10.1111/tan.13767. Epub 2019 Dec 1.


Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.

Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim YU, Pordy R, Reiner Ž, Roe MT, Tse HF, Montenegro Valdovinos PC, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Investigators.

Circulation. 2019 Dec 17;140(25):2054-2062. doi: 10.1161/CIRCULATIONAHA.119.043826. Epub 2019 Nov 11.


Comparison Between Interwoven Nitinol and Drug Eluting Stents for Endovascular Treatment of Femoropopliteal Artery Disease.

Haine A, Schmid MJ, Schindewolf M, Lenz A, Bernhard SM, Drexel H, Baumgartner I, Dopheide JF.

Eur J Vasc Endovasc Surg. 2019 Dec;58(6):865-873. doi: 10.1016/j.ejvs.2019.09.002. Epub 2019 Oct 25.


Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.

Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.

Eur Heart J. 2019 Sep 21;40(36):3010-3012. doi: 10.1093/eurheartj/ehz650. No abstract available.


2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group .

Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. No abstract available.


Serotonin is elevated in risk-genotype carriers of TCF7L2 - rs7903146.

Leiherer A, Muendlein A, Saely CH, Fraunberger P, Drexel H.

Sci Rep. 2019 Sep 6;9(1):12863. doi: 10.1038/s41598-019-49347-y.


Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.

Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA; THEMIS Steering Committee and Investigators.

Lancet. 2019 Sep 28;394(10204):1169-1180. doi: 10.1016/S0140-6736(19)31887-2. Epub 2019 Sep 1.


Ticagrelor in Patients with Stable Coronary Disease and Diabetes.

Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA; THEMIS Steering Committee and Investigators.

N Engl J Med. 2019 Oct 3;381(14):1309-1320. doi: 10.1056/NEJMoa1908077. Epub 2019 Sep 1.


Antithrombotic Therapy and Major Adverse Limb Events in Patients With Chronic Lower Extremity Arterial Disease: Systematic Review and Meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases.

Savarese G, Reiner MF, Uijl A, D Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS.

Eur Heart J Cardiovasc Pharmacother. 2019 Aug 8. pii: pvz036. doi: 10.1093/ehjcvp/pvz036. [Epub ahead of print]


Data on the association between CTRP1 and future major adverse cardiovascular events in patients undergoing coronary angiography.

Muendlein A, Leiherer A, Saely C, Ebner J, Geiger K, Brandtner EM, Vonbank A, Fraunberger P, Drexel H.

Data Brief. 2019 Jun 7;25:104109. doi: 10.1016/j.dib.2019.104109. eCollection 2019 Aug.


The age of RCT`s 3 Important Aspects of RCT`s in Cardiovascular Pharmacotherapy with examples from Lipid and Diabetes Trials.

Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, Agewall S.

Eur Heart J Cardiovasc Pharmacother. 2019 Jul 12. pii: pvz029. doi: 10.1093/ehjcvp/pvz029. [Epub ahead of print] No abstract available.


Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Jul 8;:. Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21.


SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class.

Schernthaner G, Drexel H, Moshkovich E, Zilaitiene B, Martinka E, Czupryniak L, Várkonyi T, Janež A, Ducena K, Lalić K, Tankova T, Prázný M, Smirčić Duvnjak L, Sukhareva O, Sourij H.

BMC Endocr Disord. 2019 Jun 17;19(1):64. doi: 10.1186/s12902-019-0387-y.

Supplemental Content

Loading ...
Support Center